Which statement best describes the relationship between antipsychotic potency and dyslipidemia risk?

Which statement best describes the relationship between antipsychotic potency and dyslipidemia risk?

• A. Dyslipidemia risk is highest with low-potency FGAs
• B. Dyslipidemia risk is lower with SGAs than FGAs, and within FGAs, low-potency have the lowest risk while high-potency have the highest
• C. Dyslipidemia risk does not vary with potency
• D. Dyslipidemia risk is not linked to antipsychotics

Answer: (B)

Dyslipidemia risk from antipsychotics depends on both the class and the potency of the drug. In this pattern, second-generation antipsychotics are viewed as having lower dyslipidemia risk than first-generation ones, while among first-generation agents the risk climbs with potency—from low-potency to high-potency. So the statement fits best: SGAs carry less dyslipidemia risk than FGAs, and within FGAs, low-potency have the lowest risk while high-potency have the highest. This reflects how weight and lipid effects relate to the drug’s receptor profile and potency, even though individual drugs can vary.

Dyslipidemia risk from antipsychotics depends on both the class and the potency of the drug. In this pattern, second-generation antipsychotics are viewed as having lower dyslipidemia risk than first-generation ones, while among first-generation agents the risk climbs with potency—from low-potency to high-potency. So the statement fits best: SGAs carry less dyslipidemia risk than FGAs, and within FGAs, low-potency have the lowest risk while high-potency have the highest. This reflects how weight and lipid effects relate to the drug’s receptor profile and potency, even though individual drugs can vary.